Johnson & Johnson’s COVID-19 Vaccine Draws Mixed Reactions as it Registers 66% Efficacy
On January 29th, Johnson & Johnson announced results from the Phase 3 clinical trial of its COVID-19 vaccine candidate. Results show the vaccine is 85% effective at preventing severe disease. …
Read More